accelerating drug, device & gene therapy development

Delivering Better Models to Understand Human Disease

Surrogen is providing better research models that replicate human diseases in pigs—animals that are more similar to humans than commonly-used mice by nearly every measure.

Our expertise in molecular and cellular biology, genomics, embryology, animal husbandry, and production enable disease researchers and therapeutic developers to answer questions that other models cannot.

Surrogen pigs enable a more thorough examination of the onset and progression of human disease, as well as the safety and efficacy of therapeutics designed to treat it.

Surrogen Logo Image


more than 90% of all clinical trials fail
it costs more than $1 billion to develop a single drug
Current animal models fail to predict therapeutic effectiveness in humans
there are no cures for some of the world’s most intractable diseases

focusing our work

To combat those realities, Surrogen is focused on…

developing animal models of actual human disease
Accelerating more effective human therapies to market at lower costs
Advancing research in orphan diseases
our models

The Pig Model Advantage

Surrogen’s gene-edited pigs provide an unrivaled advantaged over traditional animal models. Pigs are and/or have:

  • One of the closest non-primate species to humans
  • Organ systems highly similar to humans
  • Similar anatomy, physiology and size to human patients
  • Well-established for the use in preclinical research
  • Fast gestation periods (three months, three weeks, three days)
Genome Lab
our tools

The Genome Editing Advantage

Scientists have identified more than 10,000 single gene mutations that play roles in diseases and medical conditions. Surrogen leverages its world-leading expertise in the use of gene editing tools like transcription activator-like effector nucleases (TALENs), clustered regularly interspaced short palindromic repeats (CRISPR) and others to design optimized swine models for a wide array of disease-causing mutations identical to those in human patients. Thus, we are creating disease models in swine that are genetically and phenotypically similar to humans.

our impact

Surrogen could give pre-clinical R&D programs:

speed icon
increased speed to market
target icon
reduced failure rates
list icon
customizable options
lightbulb icon
opportunities to make better products
people icon
means to evaluate diseases with small patient populations
process icon
ways to examine interventions systematically
testing icon
ability to test for safety and efficacy before patient trials
identify icon
identify and validate disease and therapeutic biomarkers

surrogen pipeline

Cloning Stims

Surrogen has the following projects currently in development:

  • Cancer: Brain; Liver; Colorectal; Ovarian; Inherited Tumor Disposition
  • Rare Disease: Neurofibromatosis Type 1 & 2; Alpha-1-Antitrypsin Deficiency; Osteogenesis Imperfecta; Microvillus Inclusion Disease
  • Cardiovascular Diseases: Atherosclerosis; Dilated Cardiomyopathy
  • Congenital Conditions: Heart Disease
  • Hereditary & Neonatal Diseases: Polycystic Kidney Disease
  • Lifestyle Diseases: Type 1 & Type 2 Diabetes; Metabolic Syndrome; Nonalcoholic Steatohepatitis (NASH); Atherosclerosis
  • Neurodegenerative Diseases: Alzheimer’s Disease
  • Cell and Gene Therapy Models

Better models. Better research. Better results.

Contact us for information on using Surrogen’s animal models in your work.